The applicant is an assistant professor at Molecular and Cellular Oncogenesis Program at the Wistar Institute. Her overall goal is to develop effective and long-lasting treatment strategies for melanoma. This proposal serves the applicant's long-term objective of improving outcomes for melanoma patients by investigating the mechanisms of intrinsic resistance to targeted therapy in BRAF-V600E and NRAS mutant melanomas. The candidate will pursue training in research areas that are essential to foster a research niche and become an independent academic cancer researcher. A team of senior scientific advisors has been assembled to formally mentor the applicant by providing training and expertise in new research areas including proteomics, systems and computational biology, and autophagy. The mentoring team is committed to support the development of the applicant into a fully funded independent scientist. Melanoma is a highly aggressive disease with limited therapeutic options. Despite the success of BRAF inhibitors for the treatment of melanoma, responses are transient and most patients develop resistance. Therefore, a major challenge is to understand, overcome, and prevent drug resistance. This application proposes to investigate the mechanisms of intrinsic drug resistance, an important unmet medical need affecting a large subset of melanoma patients, for whom no effective therapies are available. The proposal focuses on NRAS mutant melanomas and BRAF-V6000E mutant melanomas that are intrinsically resistant to BRAF inhibitors. The overall hypothesis is that uncovering the mechanisms underlying intrinsic drug resistance in melanoma will allow designing more effective and longer lasting therapies. The applicant postulates that inhibition of BRAF induces rewiring of the system's signaling networks leading to receptor tyrosine kinase (RTK) activation and attenuated dependency on BRAF. To test this hypothesis, the expression and activation of RTKs will be evaluated in melanoma cell lines and patient-derived tumor samples grown in immunocompromised mice (patient-derived xenografts;PDX) following BRAF inhibition. Mechanistic studies will be performed to determine how inhibition of MAPK leads to RTK activation. Based on these studies rational drug combination strategies will be evaluated in melanoma cells grown as 3D tumor spheroids and in PDX models. The second working hypothesis is that by identifying critical downstream NRAS effectors, melanomas harboring mutations in NRAS can be targeted. The objective is to define the biochemical and biological consequences of silencing NRAS in melanoma cells that harbor mutations in this oncogene. To achieve this goal a candidate and an unbiased proteomic based approaches will be undertaken to identify NRAS effectors that are essential for survival of NRAS mutant melanomas. Collectively, this knowledge will be critical to develop new strategies that eliminate nearly all melanoma cells and inform the design of future clinical trials.
Melanoma is a significant public health problem, affecting almost 900,000 people in the US. The incidence of melanoma has been steadily increasing during the past decade. The NCI Surveillance, Epidemiology and End Results (SEER) Program estimates that in 2012 more than 76,000 people will be diagnosed with melanoma. Melanoma is a highly aggressive neoplasm, which tends to rapidly metastasize;patients with metastatic melanoma usually die of their disease. The 5-year relative survival rate for patients with metastatic melanoma is ~15%. In recent years significant progress has been made understanding the biology and molecular mechanisms driving this lethal disease. This knowledge has led to the development of new treatments for metastatic melanoma. However, currently available treatments are short-lived and most patients experience disease relapse as tumors become resistant to therapy. Furthermore, a large subset of patients does not respond at all to current treatments. Therefore, there is an urgent need to develop better and longer lasting therapies for melanoma. The purpose of this proposal is to unravel intrinsic drug resistance in melanoma;it is expected that this knowledge will be crucial to develop innovative therapies that will result in long-lasting responses and improved patient survival. The written critiques and criteria scores of individual reviewers are provided in essentially unedited form in the Critique section below. Please note that these critiques and criteria scores were prepared prior to the meeting and may not have been revised subsequent to any discussions at the review meeting. The Resume and Summary of Discussion section above summarizes the final opinions of the committee.
| EchevarrÃa-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10: |
| Reyes-Uribe, Patricia; Adrianzen-Ruesta, Maria Paz; Deng, Zhong et al. (2018) Exploiting TERT dependency as a therapeutic strategy for NRAS-mutant melanoma. Oncogene 37:4058-4072 |
| EchevarrÃa-Vargas, Ileabett M; Villanueva, Jessie (2017) COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE. Melanoma Manag 4:183-186 |
| Shannan, Batool; Perego, Michela; Somasundaram, Rajasekharan et al. (2016) Heterogeneity in Melanoma. Cancer Treat Res 167:1-15 |
| Krepler, Clemens; Xiao, Min; Samanta, Minu et al. (2016) Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. Oncotarget 7:71211-71222 |
| Grasso, Michael; Estrada, Michelle A; Ventocilla, Christian et al. (2016) Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation. ACS Chem Biol 11:2876-2888 |
| Chen, Hsin-Yi; Brady, Donita C; Villanueva, Jessie (2016) Double Trouble: Kinase domain duplication as a new path to drug resistance. Pigment Cell Melanoma Res 29:493-5 |
| Qin, Jie; Rajaratnam, Rajathees; Feng, Li et al. (2015) Development of organometallic S6K1 inhibitors. J Med Chem 58:305-14 |
| Chen, Hsin-Yi; Villanueva, Jessie (2015) Playing Polo-Like Kinase in NRAS-Mutant Melanoma. J Invest Dermatol 135:2352-2355 |
| Ma, Xiao-Hong; Piao, Sheng-Fu; Dey, Souvik et al. (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 124:1406-17 |
Showing the most recent 10 out of 13 publications
